Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
GLP-1RA, Topics

New Ozempic Concentrations; Potential Autoinjector in Ph1 Study

Here is a brief preview of this blast: A new Ph1 trial comparing different concentrations of semaglutide between FlexTouch, NovoPen4, and a novel injection device (DV3372) has appeared on CT.gov. In the 68-participant study, the current formulation of Ozempic (1.34mg/mL concentration delivered via FlexTouch, a.k.a. PDS290) will be compared to three more concentrated formulations of semaglutide (0.5mg/mL, 1.0mg/mL, and 2.0mg/mL). Below, FENIX analyzes the trial design, including insights regarding a potential Ozempic autoinjector and a reusable injection device, as well as the value of higher concentrations in reducing the amount of pens needed.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.